Online citations, reference lists, and bibliographies.
← Back to Search

Predictive Value Of Direct Nitrate Reductase Assay And Its Clinical Performance In The Detection Of Multi- And Extensively Drug-resistant Tuberculosis.

B. Imperiale, N. Morcillo, J. Palomino, P. Vandamme, A. Martin
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Conventional culture and drug susceptibility testing (DST) methods for Mycobacterium tuberculosis are laborious and time consuming. For this reason alternative rapid culture and DST techniques are urgently needed to shorten the time for drug-resistance detection. A total of 222 smear-positive sputum samples were evaluated by the direct nitrate reductase assay (D-NRA) on Lowenstein-Jensen medium, for the rapid and simultaneous detection of resistance to isoniazid, rifampicin, kanamycin and ofloxacin. p-Nitrobenzoic acid was also included for identification of the M. tuberculosis complex. Results were compared with the BACTEC MGIT 960 as gold standard. The general performance of the D-NRA was very good, reaching a global value of 97 %. D-NRA had a turn-around time of 16.9 days to obtain results while that of the indirect MGIT 960 system was 29 days. D-NRA is a low-cost technology, easy to set up in clinical laboratories and suitable to be used for DST of M. tuberculosis in all smear-positive samples.
This paper references
10.1016/J.IJANTIMICAG.2004.02.027
Drug susceptibility testing of Mycobacterium tuberculosis with nitrate reductase assay.
A. Coban (2004)
10.1128/JCM.44.5.1769-1775.2006
Evaluation of the GenoType Mycobacterium Assay for Identification of Mycobacterial Species from Cultures
E. Richter (2006)
10.1093/jac/dkt353
Prospective multicentre evaluation of the direct nitrate reductase assay for the rapid detection of extensively drug-resistant tuberculosis.
A. Martin (2014)
10.5588/ijtld.12.0949
Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs.
B. Imperiale (2013)
10.4103/0974-2727.72157
Evaluation of a Rapid Differentiation Test for Mycobacterium Tuberculosis from other Mycobacteria by Selective Inhibition with p-nitrobenzoic Acid using MGIT 960
Babita Sharma (2010)
10.1128/JCM.00691-07
Evaluation of Direct Detection of Mycobacterium tuberculosis Rifampin Resistance by a Nitrate Reductase Assay Applied to Sputum Samples in Cotonou, Benin
D. Affolabi (2007)
Tuberculosis situation in Argentina . Epidemiological Bulletin
N. Morcillo (2011)
10.1128/JCM.43.7.3159-3161.2005
Drug Susceptibility Testing of Mycobacterium tuberculosis by a Nitrate Reductase Assay Applied Directly on Microscopy-Positive Sputum Samples
Humberto R Musa (2005)
First evaluation in Argentina of the GenoType® MTBDRplus assay for multidrug-resistant Mycobacterium tuberculosis detection from clinical isolates and specimens.
B. Imperiale (2012)
10.5588/ijtld.10.0397
Rapid detection of multidrug-resistant Mycobacterium tuberculosis by multiplex allele-specific polymerase chain reaction.
B. Imperiale (2011)
BD BACTEC MGIT 960 SIRE kit for the antimycobacterial susceptibility testing of Mycobacterium tuberculosis
Becton Dickinson (2005)
Global Tuberculosis Control 2011, WHO Report 2011
D. Behera (2012)
10.1128/JCM.40.2.553-555.2002
Rapid and Inexpensive Drug Susceptibility Testing of Mycobacterium tuberculosis with a Nitrate Reductase Assay
K. Ängeby (2002)
Evaluation of MGIT 960 and the colorimetric-based method for tuberculosis drug susceptibility testing.
N. Morcillo (2010)
10.1093/jac/dkn139
The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
A. Martin (2008)
10.2147/IDR.S3838
New simple decontamination method improves microscopic detection and culture of mycobacteria in clinical practice
N. Morcillo (2008)
ANTI-TUBERCULOSIS DRUG RESISTANCE IN THE WORLD
A. Wright (2000)
10.1128/JCM.44.3.688-692.2006
Multicenter Laboratory Validation of the BACTEC MGIT 960 Technique for Testing Susceptibilities of Mycobacterium tuberculosis to Classical Second-Line Drugs and Newer Antimicrobials
S. Rüsch-Gerdes (2006)
10.1016/S0035-9203(98)90766-0
Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization, 1997. 228pp. Price Sw. fr 25/US$22.50 (in developing countries Sw. fir 17.50). (Reference WHO/TB/97.229)
D. Wilkinson (1998)
Drug susceptibility test in the management of chemotherapy of tuberculosis
L. B. Heifets (1991)
Multidrug and Extensively Drug-Resistant TB (M/XDRTB): 354 2010 Global Report on Surveillance and Response
WHO (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar